Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Ramiro, S, Landewé, RB, van der Heijde, D, Sepriano, A, FitzGerald, O, Ostergaard, M, Homik, J, Elkayam, O, Thorne, JC, Larche, M, Ferraccioli, G, Backhaus, M, Boire, G, Combe, B, Schaeverbeke, T, Saraux, A, Dougados, M, Rossini, M, Govoni, M, Sinigaglia, L, Cantagrel, AG, Allaart, CF, Barnabe, C, Bingham, CO, Tak, PP, van Schaardenburg, D, Hammer, HB, Dadashova, R, Hutchings, E & Paschke, J 2020, 'Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)', Annals of the Rheumatic Diseases, bind 79, nr. 4, s. 453-459. https://doi.org/10.1136/annrheumdis-2019-216819

APA

Ramiro, S., Landewé, R. B., van der Heijde, D., Sepriano, A., FitzGerald, O., Ostergaard, M., Homik, J., Elkayam, O., Thorne, J. C., Larche, M., Ferraccioli, G., Backhaus, M., Boire, G., Combe, B., Schaeverbeke, T., Saraux, A., Dougados, M., Rossini, M., Govoni, M., ... Paschke, J. (2020). Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 79(4), 453-459. https://doi.org/10.1136/annrheumdis-2019-216819

CBE

Ramiro S, Landewé RB, van der Heijde D, Sepriano A, FitzGerald O, Ostergaard M, Homik J, Elkayam O, Thorne JC, Larche M, Ferraccioli G, Backhaus M, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel AG, Allaart CF, Barnabe C, Bingham CO, Tak PP, van Schaardenburg D, Hammer HB, Dadashova R, Hutchings E, Paschke J. 2020. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases. 79(4):453-459. https://doi.org/10.1136/annrheumdis-2019-216819

MLA

Vancouver

Author

Ramiro, Sofia ; Landewé, Robert Bm ; van der Heijde, Désirée ; Sepriano, Alexandre ; FitzGerald, Oliver ; Ostergaard, Mikkel ; Homik, Joanne ; Elkayam, Ori ; Thorne, J Carter ; Larche, Margaret ; Ferraccioli, Gianfranco ; Backhaus, Marina ; Boire, Gilles ; Combe, Bernard ; Schaeverbeke, Thierry ; Saraux, Alain ; Dougados, Maxime ; Rossini, Maurizio ; Govoni, Marcello ; Sinigaglia, Luigi ; Cantagrel, Alain G ; Allaart, Cornelia F ; Barnabe, Cheryl ; Bingham, Clifton O ; Tak, Paul P ; van Schaardenburg, Dirkjan ; Hammer, Hilde Berner ; Dadashova, Rana ; Hutchings, Edna ; Paschke, Joel. / Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). I: Annals of the Rheumatic Diseases. 2020 ; Bind 79, Nr. 4. s. 453-459.

Bibtex

@article{dc333a9ac7b543ccb14b4f6426917f67,
title = "Is treat-to-target really working in rheumatoid arthritis?: a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)",
abstract = "OBJECTIVES: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.METHODS: RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definitions. The association between T2T and remission was tested in generalised estimating equations models.RESULTS: In total 4356 visits of 571 patients (mean (SD) age: 56 (13) years, 78% female) were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later (OR (95% CI): 1.03 (0.92 to 1.16)), but sustained T2T resulted in an increased likelihood of achieving DAS44 remission (OR: 1.19 (1.03 to 1.39)). Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16 to 1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49 to 1.52).CONCLUSION: In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.",
keywords = "Adult, Aged, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/drug therapy, Blood Sedimentation, C-Reactive Protein/immunology, Clinical Decision-Making, Cohort Studies, Female, Humans, Longitudinal Studies, Male, Middle Aged, Patient Care Planning, Remission Induction, Rheumatoid Factor/immunology, Tumor Necrosis Factor Inhibitors/therapeutic use, treat-to-target, rheumatoid arthritis, remission",
author = "Sofia Ramiro and Landew{\'e}, {Robert Bm} and {van der Heijde}, D{\'e}sir{\'e}e and Alexandre Sepriano and Oliver FitzGerald and Mikkel Ostergaard and Joanne Homik and Ori Elkayam and Thorne, {J Carter} and Margaret Larche and Gianfranco Ferraccioli and Marina Backhaus and Gilles Boire and Bernard Combe and Thierry Schaeverbeke and Alain Saraux and Maxime Dougados and Maurizio Rossini and Marcello Govoni and Luigi Sinigaglia and Cantagrel, {Alain G} and Allaart, {Cornelia F} and Cheryl Barnabe and Bingham, {Clifton O} and Tak, {Paul P} and {van Schaardenburg}, Dirkjan and Hammer, {Hilde Berner} and Rana Dadashova and Edna Hutchings and Joel Paschke",
note = "COPECARE",
year = "2020",
month = apr,
doi = "10.1136/annrheumdis-2019-216819",
language = "English",
volume = "79",
pages = "453--459",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "4",

}

RIS

TY - JOUR

T1 - Is treat-to-target really working in rheumatoid arthritis?

T2 - a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

AU - Ramiro, Sofia

AU - Landewé, Robert Bm

AU - van der Heijde, Désirée

AU - Sepriano, Alexandre

AU - FitzGerald, Oliver

AU - Ostergaard, Mikkel

AU - Homik, Joanne

AU - Elkayam, Ori

AU - Thorne, J Carter

AU - Larche, Margaret

AU - Ferraccioli, Gianfranco

AU - Backhaus, Marina

AU - Boire, Gilles

AU - Combe, Bernard

AU - Schaeverbeke, Thierry

AU - Saraux, Alain

AU - Dougados, Maxime

AU - Rossini, Maurizio

AU - Govoni, Marcello

AU - Sinigaglia, Luigi

AU - Cantagrel, Alain G

AU - Allaart, Cornelia F

AU - Barnabe, Cheryl

AU - Bingham, Clifton O

AU - Tak, Paul P

AU - van Schaardenburg, Dirkjan

AU - Hammer, Hilde Berner

AU - Dadashova, Rana

AU - Hutchings, Edna

AU - Paschke, Joel

N1 - COPECARE

PY - 2020/4

Y1 - 2020/4

N2 - OBJECTIVES: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.METHODS: RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definitions. The association between T2T and remission was tested in generalised estimating equations models.RESULTS: In total 4356 visits of 571 patients (mean (SD) age: 56 (13) years, 78% female) were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later (OR (95% CI): 1.03 (0.92 to 1.16)), but sustained T2T resulted in an increased likelihood of achieving DAS44 remission (OR: 1.19 (1.03 to 1.39)). Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16 to 1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49 to 1.52).CONCLUSION: In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.

AB - OBJECTIVES: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.METHODS: RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definitions. The association between T2T and remission was tested in generalised estimating equations models.RESULTS: In total 4356 visits of 571 patients (mean (SD) age: 56 (13) years, 78% female) were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later (OR (95% CI): 1.03 (0.92 to 1.16)), but sustained T2T resulted in an increased likelihood of achieving DAS44 remission (OR: 1.19 (1.03 to 1.39)). Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16 to 1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49 to 1.52).CONCLUSION: In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.

KW - Adult

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Rheumatoid/drug therapy

KW - Blood Sedimentation

KW - C-Reactive Protein/immunology

KW - Clinical Decision-Making

KW - Cohort Studies

KW - Female

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Patient Care Planning

KW - Remission Induction

KW - Rheumatoid Factor/immunology

KW - Tumor Necrosis Factor Inhibitors/therapeutic use

KW - treat-to-target

KW - rheumatoid arthritis

KW - remission

U2 - 10.1136/annrheumdis-2019-216819

DO - 10.1136/annrheumdis-2019-216819

M3 - Journal article

C2 - 32094157

VL - 79

SP - 453

EP - 459

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -

ID: 61745033